Horizon Pharma plc (HZNP) : Analyst Rating Update

Horizon Pharma plc (HZNP) : The consensus on Horizon Pharma plc (HZNP) based on 7 analyst recommendation on the company stock is 1.47, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Horizon Pharma plc (HZNP) : Average target price received by Horizon Pharma plc (HZNP) is $32.29 with an expected standard deviation of $8.46. The most aggressive target on the stock is $45, whereas the most downbeat target is $24. 7 financial analysts are currently covering the stock.

Horizon Pharma plc (NASDAQ:HZNP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $16.57 and $16.33 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $17.57. The buying momentum continued till the end and the stock did not give up its gains. It closed at $17.51, notching a gain of 4.72% for the day. The total traded volume was 5,617,777 . The stock had closed at $16.72 on the previous day.

Also, BMO Capital initiates coverage on Horizon Pharma plc (NASDAQ:HZNP).The analysts at the brokerage house have a current rating of Outperform on the shares. The rating by the firm was issued on June 29, 2016. The company shares have dropped -50.81% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $39.49 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $16.79 and the 200 Day Moving Average price is recorded at $17.12.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.